Health CareSnapshot 2026-07-31
Reading ALUR? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Management is running behind on a stated commitment.
View ThesisRevenue is contracting — down about 55% over the past year.
View GrowthManagement screens weak on capital allocation, the balance sheet.
View ManagementThis stock is highly volatile — it swings about 7% on a typical day and fell roughly 92% in its worst 12-month stretch.
View RiskALUR's growth depends on improving management and steady sector trends. Recent performance has been steady, but management is unsteady and disruptive. ALUR trades below typical sector peers. This suggests that the stock may not reflect its potential. If ALUR cuts guidance on the next call, it could negatively impact the stock. Peer multiples imply a price about 12% above where it trades.
Trailing returns as of 2026-06-17. ALUR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 2 analysts currently covering ALUR (as of Jun 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care (broad) — fair value, gap to price, and forward P/E.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-06-17. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
